Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Xrayser thinks long and hard about Viagra relicensing

Xrayser goes x-rated to examine why some health professionals still struggle to talk sensibly about the reclassification of sildenafil.

There's not long now before there’s rejoicing in the streets and joy to the world on the day that sildenafil is relicensed as a Pharmacy (P) medicine. Soon those interminable adverts for river cruises scattered among the re-runs of Midsomer Murders will be replaced by a smiling white couple in their 50s, dancing around their middle-class living room, while a voiceover says: “Lancelot sildenafil tablets have brought back the spring in their step…”

Surely over-the-counter (OTC) sildenafil is a good thing, because we have years of experience of use and because 20% of websites are already devoted to selling it?

Not according to our dispenser, whose first comment was: “Will they need a private conversation, like emergency hormone contraception (EHC)? Well I’m not going into a room alone to talk to some old letch who can’t get his flag flying!”

And there is our problem. We’ve reached the point where we can talk about piles, nits, worms and thrush, and treat with respect people who come in for EHC or chlamydia treatment, but when it comes to Ascension Deficit Disorder, we step right back into a Carry On film.

It’s not just pharmacy staff. At the surgery clinical meeting, I mentioned the possible reclassification of sildenafil, only for an entire room of doctors and nurses to respond with: “Glad you raised that”; “Can we expect some hard selling?”; and "There’ll be some stiff competition!” This was accompanied by a load of playground giggling.

In truth, this will not be an easy OTC sale. Presumably the WWHAM questions they need to ask will go something along the lines of:

Who’s it for?  Well I'm taking it, but really it's for the missus. She’s started on some hormone replacement therapy (HRT) and now she can’t keep her hands off me.

What are the symptoms? Ah, you know, the little soldier – Private Business – he’s not standing to attention when on active duty.

How long… Wouldn't you like to know. 

What action have you taken? A couple of years ago I paid 40 quid on the internet for 10 blue pills, but they must have been fakes. I might as well have eaten blue smarties for all the good they did.

Any other medication? Not really. Unless you count my heart medication, beta-blockers and nitrates…

I anticipate most people will log onto eBay or Amazon to stock up. This will quickly be followed by tabloid stories about drinks being spiked with sildenafil, sildenafil-fuelled swingers parties in the home counties, and hospital A&E departments full of old men with priapism. Yet this won’t stop huge sales of a drug that lists as a possible side effect “sudden cardiac death”.

But whatever happens, don’t – for God’s sake – let Jeremy Hunt get wind of this. He already thinks we’re funded through the sale of sandwiches and shampoo, and if he hears that we’re selling 'Viagra' – or 'sex drugs' as the tabloids will no doubt call them – he’ll knock another £250 million off the global sum.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD001114

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel